Brokerages expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post earnings per share of ($0.55) for the current quarter, according to Zacks. Five analysts have provided estimates for Intellia Therapeutics’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.64). Intellia Therapeutics reported earnings per share of ($0.61) during the same quarter last year, which suggests a positive year over year growth rate of 9.8%. The firm is expected to announce its next quarterly earnings results on Wednesday, March 13th.

According to Zacks, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current fiscal year, with EPS estimates ranging from ($2.20) to ($1.89). For the next year, analysts expect that the firm will report earnings of ($2.49) per share, with EPS estimates ranging from ($3.35) to ($1.18). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Intellia Therapeutics.

NTLA has been the subject of a number of research analyst reports. BidaskClub upgraded Intellia Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. Zacks Investment Research cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 6th. BTIG Research started coverage on Intellia Therapeutics in a report on Thursday. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a report on Wednesday, October 31st. Finally, Leerink Swann started coverage on Intellia Therapeutics in a report on Tuesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $31.50.

A number of institutional investors have recently made changes to their positions in NTLA. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 27.5% during the 3rd quarter. ARK Investment Management LLC now owns 5,753,790 shares of the company’s stock valued at $164,673,000 after acquiring an additional 1,240,206 shares during the period. BlackRock Inc. boosted its holdings in Intellia Therapeutics by 48.4% during the 2nd quarter. BlackRock Inc. now owns 2,556,299 shares of the company’s stock valued at $69,940,000 after acquiring an additional 833,337 shares during the period. Rehmann Capital Advisory Group purchased a new position in Intellia Therapeutics during the 3rd quarter valued at about $14,409,000. Vanguard Group Inc boosted its holdings in Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc now owns 2,653,165 shares of the company’s stock valued at $75,934,000 after acquiring an additional 287,682 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in Intellia Therapeutics by 12.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,653,165 shares of the company’s stock valued at $75,934,000 after acquiring an additional 287,682 shares during the period. Institutional investors own 69.09% of the company’s stock.

Shares of NASDAQ NTLA traded up $0.29 during mid-day trading on Wednesday, reaching $13.73. 60,987 shares of the company’s stock were exchanged, compared to its average volume of 523,890. The stock has a market cap of $582.91 million, a PE ratio of -7.30 and a beta of 2.91. Intellia Therapeutics has a 52-week low of $11.03 and a 52-week high of $35.99.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.